Cadrenal Therapeutics, Inc. Common Stock
General ticker "CVKD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $16.9M (TTM average)
Cadrenal Therapeutics, Inc. Common Stock does not follow the US Stock Market performance with the rate: -29.2%.
Estimated limits based on current volatility of 6.4%: low 0.94$, high 1.06$
Factors to consider:
- Total employees count: 5 (+25.0%) as of 2025
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Manufacturing issues, Inability to raise capital, Lack of market acceptance
- Current price 67.8% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.92$, 9.89$]
- 2026-12-31 to 2027-12-31 estimated range: [1.81$, 6.24$]
Financial Metrics affecting the CVKD estimates:
- Negative: with PPE of -1.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -0.04 <= 2.08
- Negative: 58.56 < Shareholder equity ratio, % of 63.30 <= 69.38
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term CVKD quotes
Long-term CVKD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $7.63MM | $10.96MM | $13.46MM |
| Operating Income | $-7.63MM | $-10.96MM | $-13.46MM |
| Non-Operating Income | $-0.72MM | $0.31MM | $0.22MM |
| Interest Expense | $0.00MM | $0.00MM | $0.00MM |
| R&D Expense | $4.08MM | $4.21MM | $4.10MM |
| Income(Loss) | $-8.36MM | $-10.65MM | $-13.24MM |
| Net Income(Loss)* | $-8.36MM | $-10.65MM | $-13.24MM |
| Stockholders Equity | $7.69MM | $7.44MM | $2.74MM |
| Assets | $8.52MM | $10.12MM | $4.33MM |
| Operating Cash Flow | $-3.53MM | $-7.36MM | $-12.60MM |
| Capital expenditure | $0.00MM | $0.01MM | $0.01MM |
| Investing Cash Flow | $-0.00MM | $-0.01MM | $-0.01MM |
| Financing Cash Flow | $11.90MM | $8.98MM | $6.60MM |
| Earnings Per Share** | $-9.63 | $-8.73 | $-6.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.